FIMECS Received A Notice for Patent Allowance

Kanagawa, Japan, 22nd July 2024 – FIMECS, Inc. ("FIMECS"), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that FIMECS received a notice of patent allowance for a substance patent (Application No.: JP2020534723A) of XIAP inhibitors (Heterocyclic compound) from Japan patent office.

The XIAP inhibitors granted a patent have a novel structure, bind to XIAP, an E3 ligase, and exhibit anti-tumor activity. In addition, FIMECS focusing technology,targeted protein degradation, induces protein degradation by compounds that bind to E3 ligases like XIAP. FIMECS is investigating and developing degrader compounds using the granted compounds.

This is the second country in which this patent has been granted, following the United States (Application No.: 17/263,580) last year. This patent has been filed or are pending in Europe, China, and other countries. It is expected that FIMECS intellectual property will be strengthened step by step in the future.

About FIMECS, Inc.

FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently 'undruggable' targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects. https://www.fimecs.com/eng/

About RaPPIDS™

RaPPIDS™ (Rapid Protein Proteolysis Inducer Discovery System) is one of the proprietary drug discovery platforms of FIMECS, Inc. used to generate therapeutic candidates of the targeted protein degrader. The platform allows synthesizing and evaluating various degraders quickly based on the company's proprietary know-how and diversity-oriented synthesis, and delivery of the drug candidates with the best combination of target protein binders, linkers, and E3 ligase binders. Moreover, RaPPIDS™ platform enables the discovery of novel E3 ligase binders, which is expected to dramatically expand the range of target proteins that can be degraded.

# # #

FIMECS, Inc. Media and Investor Contact:
FIMECS, Inc.
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan
Tel: +81-466-96-0261
Email: info@fimecs.com